1. Home
  2. ONC vs DTE Comparison

ONC vs DTE Comparison

Compare ONC & DTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • DTE
  • Stock Information
  • Founded
  • ONC 2010
  • DTE 1903
  • Country
  • ONC Switzerland
  • DTE United States
  • Employees
  • ONC N/A
  • DTE N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • DTE Electric Utilities: Central
  • Sector
  • ONC Health Care
  • DTE Utilities
  • Exchange
  • ONC Nasdaq
  • DTE Nasdaq
  • Market Cap
  • ONC 34.8B
  • DTE 27.8B
  • IPO Year
  • ONC N/A
  • DTE N/A
  • Fundamental
  • Price
  • ONC $310.06
  • DTE $141.71
  • Analyst Decision
  • ONC Strong Buy
  • DTE Buy
  • Analyst Count
  • ONC 10
  • DTE 11
  • Target Price
  • ONC $350.00
  • DTE $148.60
  • AVG Volume (30 Days)
  • ONC 227.5K
  • DTE 919.2K
  • Earning Date
  • ONC 11-06-2025
  • DTE 10-30-2025
  • Dividend Yield
  • ONC N/A
  • DTE 3.07%
  • EPS Growth
  • ONC N/A
  • DTE 3.66
  • EPS
  • ONC N/A
  • DTE 6.93
  • Revenue
  • ONC $4,562,002,000.00
  • DTE $14,201,000,000.00
  • Revenue This Year
  • ONC $887.89
  • DTE $10.44
  • Revenue Next Year
  • ONC $22.45
  • DTE $4.48
  • P/E Ratio
  • ONC N/A
  • DTE $20.46
  • Revenue Growth
  • ONC 47.33
  • DTE 14.55
  • 52 Week Low
  • ONC $170.99
  • DTE $115.59
  • 52 Week High
  • ONC $355.30
  • DTE $143.79
  • Technical
  • Relative Strength Index (RSI)
  • ONC 41.01
  • DTE 54.33
  • Support Level
  • ONC $306.00
  • DTE $140.89
  • Resistance Level
  • ONC $319.57
  • DTE $143.42
  • Average True Range (ATR)
  • ONC 8.04
  • DTE 1.86
  • MACD
  • ONC -2.94
  • DTE -0.07
  • Stochastic Oscillator
  • ONC 8.64
  • DTE 50.24

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

About DTE DTE Energy Company

DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.

Share on Social Networks: